NO931378L - Indol-derivater - Google Patents

Indol-derivater

Info

Publication number
NO931378L
NO931378L NO93931378A NO931378A NO931378L NO 931378 L NO931378 L NO 931378L NO 93931378 A NO93931378 A NO 93931378A NO 931378 A NO931378 A NO 931378A NO 931378 L NO931378 L NO 931378L
Authority
NO
Norway
Prior art keywords
aryl
alkyl
hydrogen
nr5r6
compounds
Prior art date
Application number
NO93931378A
Other languages
English (en)
Other versions
NO931378D0 (no
NO305121B1 (no
Inventor
John Eugene Macor
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO931378(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO931378D0 publication Critical patent/NO931378D0/no
Publication of NO931378L publication Critical patent/NO931378L/no
Publication of NO305121B1 publication Critical patent/NO305121B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO931378A 1990-10-15 1993-04-14 AnalogifremgangsmÕte for fremstilling av terapeutisk aktive indol-derivater NO305121B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15
PCT/US1991/007194 WO1992006973A1 (en) 1990-10-15 1991-10-08 Indole derivatives

Publications (3)

Publication Number Publication Date
NO931378D0 NO931378D0 (no) 1993-04-14
NO931378L true NO931378L (no) 1993-04-14
NO305121B1 NO305121B1 (no) 1999-04-06

Family

ID=24393510

Family Applications (3)

Application Number Title Priority Date Filing Date
NO931378A NO305121B1 (no) 1990-10-15 1993-04-14 AnalogifremgangsmÕte for fremstilling av terapeutisk aktive indol-derivater
NO985607A NO985607D0 (no) 1990-10-15 1998-12-01 FremgangsmÕte for fremstilling av indol-derivater
NO2001019C NO2001019I1 (no) 1990-10-15 2001-11-09 Eletriptan

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO985607A NO985607D0 (no) 1990-10-15 1998-12-01 FremgangsmÕte for fremstilling av indol-derivater
NO2001019C NO2001019I1 (no) 1990-10-15 2001-11-09 Eletriptan

Country Status (33)

Country Link
EP (1) EP0592438B1 (no)
JP (2) JP2575272B2 (no)
KR (1) KR0179053B1 (no)
CN (1) CN1039322C (no)
AT (1) ATE157361T1 (no)
AU (1) AU651637B2 (no)
BG (1) BG61975B1 (no)
BR (2) BR9106978A (no)
CA (1) CA2091562C (no)
DE (3) DE9190141U1 (no)
DK (1) DK0592438T5 (no)
EG (1) EG20224A (no)
ES (1) ES2104733T3 (no)
FI (1) FI105812B (no)
GR (1) GR3025087T3 (no)
HU (2) HUT64326A (no)
IE (1) IE913555A1 (no)
IL (3) IL99701A (no)
LU (1) LU90902I2 (no)
MX (1) MX9101606A (no)
MY (1) MY111683A (no)
NL (1) NL300070I2 (no)
NO (3) NO305121B1 (no)
NZ (2) NZ270675A (no)
OA (1) OA09874A (no)
PL (3) PL168919B1 (no)
PT (1) PT99218B (no)
RO (1) RO111767B1 (no)
RU (1) RU2095360C1 (no)
SG (1) SG54270A1 (no)
WO (1) WO1992006973A1 (no)
YU (1) YU48088B (no)
ZA (1) ZA918156B (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
HUT69705A (en) * 1991-11-25 1995-09-28 Pfizer Indole derivatives
TW288010B (no) * 1992-03-05 1996-10-11 Pfizer
CZ281763B6 (cs) * 1992-04-07 1997-01-15 Pfizer Inc. Indolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy
SK278182B6 (en) * 1992-04-10 1996-03-06 Pfizer Acylaminoindole derivatives as 5-ht1 agonists, method of their preparation and pharmaceutical compositions containing these matters their use and semifinished products of preparation proces
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (no) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
EP0695301B1 (en) * 1993-04-22 1996-10-30 Pfizer Limited Indole derivatives as 5-ht1-like agonists for use in migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
HUT75646A (en) * 1993-08-31 1997-05-28 Pfizer 5-arylindole derivatives and pharmaceutical compositions containing them
AU3162695A (en) * 1994-08-03 1996-03-04 Asta Medica Aktiengesellschaft Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
DK0804433T3 (da) * 1994-10-12 2002-10-14 Pfizer Res & Dev Indolderivat til behandling af migræne
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
CN1184425A (zh) * 1995-03-20 1998-06-10 伊莱利利公司 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
AU3170099A (en) * 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US6515141B1 (en) * 1999-08-26 2003-02-04 Fujisawa Pharmaceutical Co., Ltd. Process for the preparation of indole derivatives or salts thereof
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
CN100364991C (zh) 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
WO2006134468A1 (en) 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasitites
WO2006079999A2 (en) * 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
IT1393700B1 (it) * 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011024039A1 (en) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthesis of novel 5-(2-(phenylsulfonyl)ethyl)-1h-indole derivatives
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2017125351A1 (en) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
US20230346746A1 (en) 2020-01-22 2023-11-02 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, S.A. Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (no) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
MY111683A (en) 2000-11-30
BR9106978A (pt) 1993-09-28
JP2677777B2 (ja) 1997-11-17
CN1039322C (zh) 1998-07-29
JPH093063A (ja) 1997-01-07
DK0592438T5 (da) 1999-12-06
OA09874A (en) 1994-09-15
MX9101606A (es) 1992-06-05
CA2091562A1 (en) 1992-04-16
HU9301098D0 (en) 1993-07-28
AU651637B2 (en) 1994-07-28
DE69127468T2 (de) 1998-01-02
ES2104733T3 (es) 1997-10-16
NO931378D0 (no) 1993-04-14
SG54270A1 (en) 1998-11-16
ZA918156B (en) 1993-04-14
CN1062529A (zh) 1992-07-08
IL115117A (en) 1996-11-14
JP2575272B2 (ja) 1997-01-22
IL99701A0 (en) 1992-08-18
DE10299004I1 (de) 2002-05-08
HU225055B1 (en) 2006-05-29
PT99218B (pt) 1999-04-30
AU8950491A (en) 1992-05-20
NZ270675A (en) 1997-07-27
DE9190141U1 (no) 1993-07-15
NO985607L (no) 1998-12-01
NL300070I1 (nl) 2002-02-01
IL115117A0 (en) 1995-12-08
RO111767B1 (ro) 1997-01-30
HUT64326A (en) 1993-12-28
FI105812B (fi) 2000-10-13
WO1992006973A1 (en) 1992-04-30
EP0592438A1 (en) 1994-04-20
BG97632A (bg) 1994-03-31
YU48088B (sh) 1997-01-08
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
PL170330B1 (pl) 1996-11-29
PT99218A (pt) 1992-09-30
CA2091562C (en) 2001-03-27
BG61975B1 (bg) 1998-11-30
FI931667A (fi) 1993-04-14
DE69127468D1 (de) 1997-10-02
NO2001019I1 (no) 2001-12-03
KR0179053B1 (ko) 1999-03-20
JPH05507288A (ja) 1993-10-21
PL169987B1 (en) 1996-09-30
RU2095360C1 (ru) 1997-11-10
NO305121B1 (no) 1999-04-06
DK0592438T3 (da) 1997-09-29
NO985607D0 (no) 1998-12-01
EP0592438B1 (en) 1997-08-27
LU90902I2 (fr) 2002-06-26
IL99701A (en) 1996-10-31
ATE157361T1 (de) 1997-09-15
PL168919B1 (pl) 1996-05-31
YU165391A (sh) 1994-01-20
BR1100080A (pt) 2000-06-06
NL300070I2 (nl) 2002-03-01
DE10299004I2 (de) 2006-03-16
IE913555A1 (en) 1992-04-22
NZ240217A (en) 1995-05-26
EG20224A (en) 1997-12-31

Similar Documents

Publication Publication Date Title
NO931378D0 (no) Indol-derivater
NO960818L (no) 5-Arylindol-derivater
MY108909A (en) Indole derivatives

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Spc suppl protection certif: SPC/NO 2001 019

Filing date: 20011109

Extension date: 20151214

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2001019